Current intravitreal pharmacologic therapies for diabetic macular edema

References

• International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation. 2013. Available from http://www.idf.org/diabetesatlas. Accessed 02, 2015
   Google Scholar
• Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552–63
   PubMed Web of Science ®Google Scholar
• National Diabetes Statistics Report 2014. Centers for Disease Control. CDC.gov. Accessed 02, 2015
   Google Scholar
• Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998–1003
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801–15
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102:647–61
   PubMed Web of Science ®Google Scholar
• Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1–32
   PubMed Web of Science ®Google Scholar
• Klein R, Moss SE, Klein BEK, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. The incidence of macular edema. Ophthalmology 1989;96:1501–10
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BEK. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998–1003
   PubMed Web of Science ®Google Scholar
• Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 2014;132:1334–40
   PubMed Web of Science ®Google Scholar
• Davidov E, Breitscheidel L, Clouth J, et al. Diabetic retinopathy and health-related quality of life. Graefes Arch Clin Exp Ophthalmol 2009;247:267–72
   PubMed Web of Science ®Google Scholar
• Knudsen ST, Bek T, Poulsen PL, et al. Macular edema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy. Diabetes Care 2002;25:2328–34
   PubMed Web of Science ®Google Scholar
• Rotsos TG, Moschos MM. Cystoid macular edema. J Clin Ophthalmol 2008;2:919–30
   PubMedGoogle Scholar
• Wirostko B, Wong TY, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 2008;27:608–21
   PubMed Web of Science ®Google Scholar
• Morigi M, Angioletti S, Imberti B, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 1998;101:1905–15
   PubMed Web of Science ®Google Scholar
• Cai W, Rook SL, Jiang ZY, et al. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth. Invest Ophthalmol Vis Sci 2000;41:1885–93
   PubMed Web of Science ®Google Scholar
• Miyamoto N, de Kozak Y, Jeanny JC, et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 2007;50:461–70
   PubMed Web of Science ®Google Scholar
• Vinores SA, Youssri AL, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and nonischemic human and experimental retinal disease. Histol Histopathol 1997;12:99–109
   PubMed Web of Science ®Google Scholar
• Shams JN. Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 2006;19:335–44
   PubMedGoogle Scholar
• Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous Injections of Vascular Endothelial Growth Factor Produce Retinal Ischemia and Microangiopathy in an Adult Primate. Ophthalmology 1996;103:1620–8
   Google Scholar
• Chibber R, Molinatti PA, Rosatto N, et al. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia 1997;40:156–64
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615–25
   PubMed Web of Science ®Google Scholar
• Harbour JW, Smiddy WE, Flynn HWJr, et al. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 1996;121:405–13
   PubMed Web of Science ®Google Scholar
• Lewis H, Abrams GW, Blumenkranz MS, et al. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992;99:753–9
   PubMed Web of Science ®Google Scholar
• Colucciello M. Diabetic retinopathy- Control of systemic factors preserves vision. Postgrad Med 2004;116:57–64
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE. The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab Rev 1989;5:559–70
   PubMed Web of Science ®Google Scholar
• Chew EY, Klein ML, Ferris FL3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy.Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079–84
   PubMed Web of Science ®Google Scholar
• Friedman EA, L’Esperance FA, Brown CD, et al. Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease. Kidney Int 2003;64:S57–63
   Google Scholar
• Mason RH, West SD, Kiire CA, et al. High prevalence of sleep disordered breathing in patients with diabetic macular edema. Retina 2012;32:1791–8
   PubMed Web of Science ®Google Scholar
• Nesmith BL, Ihnen M, Schaal S. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea. Retina 2014;34:2423–30
   PubMed Web of Science ®Google Scholar
• Colucciello M. Vision Loss from macular edema associated with rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol 2005;123:1273–5
   PubMed Web of Science ®Google Scholar
• Ryan EH, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina 2006;26:562–70
   PubMed Web of Science ®Google Scholar
• Ceriello A. The emerging challenge in diabetes: The “metabolic memory”. Vascul Pharmacol 2012;57:133–8
   PubMed Web of Science ®Google Scholar
• Aschner PJ, Ruiz AJ. Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther 2012;14:S68–74
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796–806
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064–77
   PubMed Web of Science ®Google Scholar
• Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820–8
   PubMed Web of Science ®Google Scholar
• Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated bloodretinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408–13
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–7
   PubMed Web of Science ®Google Scholar
• Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133:70–7
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860–7
   PubMed Web of Science ®Google Scholar
• Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). 12-month data: report 2. Ophthalmology 2010;117:1078–86
   PubMed Web of Science ®Google Scholar
• Michaelides M, Fraser-Bell S, Hamilton RD, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study): report 1. Retina 2010;30:781–6
   PubMed Web of Science ®Google Scholar
• Yannuzzi NA, Klufas MA, Quach L, et al. Evaluation of compounded bevacizu- mab prepared for intravitreal injection. JAMA Ophthalmol 2015;133:32–9
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009;116:2175–81
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2010;117:2146–51
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network; Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119:2312–18
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615–25
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399–405
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al.; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789–801
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol 2009;93:144–9
   PubMed Web of Science ®Google Scholar
• Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The da VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology 2011;118:1819–26
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal Aflibercept for diabetic macular edema. Ophthalmology 2014;121:2247–54
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:8
   Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema — relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch Ophthalmol 1995;113:1144–55
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET, et al. for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for Neovascular Age-Related Macular Degeneration. N Engl J Med 2004;351:2805–16
   PubMed Web of Science ®Google Scholar
• Loftus JV, Sultan MB, Pleil AM. Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. Invest Ophthalmol Vis Sci 2011;52:7498–505
   PubMed Web of Science ®Google Scholar
• Pacella E, La Torre G, Impallara D, et al. Efficacy and safety of the intravitreal treatment of diabetic macular edema with pegaptanib: a 12-month follow-up. Clin Ther 2013;164:e121–6
   Google Scholar
• Sivaprasad S, Browning RC, Starita C. An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema. Clin Ophthalmol 2014;8:1565–71
   PubMedGoogle Scholar
• Elwyn H. Diabetic retinitis. Arch Ophthalmol 1945;34:187–90
   Web of Science ®Google Scholar
• Nauck M, Karakiulakis G, Perruchoud A, et al. Corticosteriods inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309–15
   PubMed Web of Science ®Google Scholar
• Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 1997;16:398–406
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE, Attar M, Acheampong A, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80–6
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE, Burke JA, Peng Q, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2011;52:4605–9
   PubMed Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915–23
   PubMed Web of Science ®Google Scholar
• Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: The BEVORDEX study. Ophthalmology 2014;121:2473–81
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort RJr, et al. Three year, randomized, sham controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904–14
   PubMed Web of Science ®Google Scholar
• Medicine and Healthcare Products Regulatory Agency, “Iluvien 190 micrograms intravitreal implant in applicator: summary of product characteristics”. 2012. Available from http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con171936.pdf
   Google Scholar
• Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117:1393–9
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125–32
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long term benefit of sustained delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626–35
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema,”. Ophthalmology 2008;115:1447–9
   PubMed Web of Science ®Google Scholar
• Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245–51
   PubMed Web of Science ®Google Scholar
• Chu YK, Chung EJ, Kwon OW, Lee JH, Koh HJ. Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection. Eye 2008;22:895–9
   PubMed Web of Science ®Google Scholar
• Smithen LM, Ober MD, Maranan L, et al. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740–3
   PubMed Web of Science ®Google Scholar
• Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010;23:460–8
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232–9
   PubMed Web of Science ®Google Scholar
• Hapani S, Sher A, Chu D, et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: ameta-analysis. Oncology 2010;79:27–38
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487–94
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semi Oncol 2006;33:S26–34
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic Bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four week results of an open label clinical study. Ophthalmology 2006;113(11):2002–11
   PubMed Web of Science ®Google Scholar
• Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014;98:1636–41
   PubMed Web of Science ®Google Scholar
• Avery RL. What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol 2014;98:i7–i10
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537–48
   PubMed Web of Science ®Google Scholar
• Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007;13:5341–7
   PubMed Web of Science ®Google Scholar
• Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009;7:171–81
   PubMed Web of Science ®Google Scholar
• CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–908
   PubMed Web of Science ®Google Scholar
• Thulliez M, Angoulvant D, Le Lez ML, et al. Cardiovascular Events and Bleeding Risk Associated With Intravitreal Antivascular Endothelial Growth Factor Monoclonal Antibodies: Systematic Review and Meta-analysis. JAMA Ophthalmol 2014;132:1317–26
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609–14
   PubMed Web of Science ®Google Scholar
• Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol 2005;19:122–7
   PubMedGoogle Scholar
• Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386–90
   PubMed Web of Science ®Google Scholar
• Detry-Morel M, Escarmelle A, Hermans I. Refractory ocular hypertension secondary to intravitreal injection of triamcinolone acetonide. Bull Soc Belge Ophtalmol 2004;292:45–51
   PubMedGoogle Scholar
• Jonas JB, Degenring R, Vossmerbauemer U, et al. Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide. Eur J Ophthalmol 2005;15:462–4
   PubMed Web of Science ®Google Scholar
• Meredith TA, McCannel CA, Barr C. Postinjection endophthalmitis in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology 2015; pii: S0161-6420(14)01044-6; 10.1016/j.ophtha.2014.10.027. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Bhavsar AR, Ip MS, Glassman AR. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007;144:454–6
   PubMed Web of Science ®Google Scholar
• Carrero JL, Barcia MG, Flores IP. Sterile endophthalmitis after benzyl alcohol-filtered triamcinolone acetonide injection. Arch Ophthalmol 2008;126:142–3
   PubMed Web of Science ®Google Scholar
• Lima LH, Zweifel SA, Engelbert M, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina 2009;29:1213–17
   PubMed Web of Science ®Google Scholar
• Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute Intraocular Inflammation after Intravitreous Injections of Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. Ophthalmology 2008;115:1911.e1–.e1
   Google Scholar
• Chong DY, Anand R, Williams PD, et al. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina 2010;30:1432–40
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–31
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–44
   PubMed Web of Science ®Google Scholar
• Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95–113
   PubMed Web of Science ®Google Scholar
• Meyer CH, Michels S, Rodrigues EB, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 2011;89:70–5
   PubMed Web of Science ®Google Scholar
• Maturi R. DARPin Presentation. American Society of Retina Specialist Meeting, San Diego, CA. 2014
   Google Scholar
• Peter A, Campochiaro PA, Roomasa Channa R, Brian B, Berger BB, et al. Treatment of Diabetic Macular Edema With a Designed Ankyrin Repeat Protein That Binds Vascular Endothelial Growth Factor: A Phase I/II Study. Am J Ophthalmol 2013;155:697–704; e2
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Boyer DS, Campochiaro PA, et al. Integrin Peptide Therapy: The Latest Human Clinical Update. Paper presented at: American Academy of Ophthalmology Annual Meeting; 12 November 2012; Chicago
   Google Scholar
• Brigell M, Campochiaro P, Sophie R, et al. “A Phase 1b/2a Open-label, Multiple-ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema”. Presented at the Association for Research in Vision and Ophthalmology Meeting, 2014
   Google Scholar
• Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)–Full Text View–ClinicalTrials.gov. clinicaltrials.gov. Available from http://clinicaltrials.gov/ct2/show/NCT01024998. Accessed 02, 2015
   Google Scholar